These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24834449)

  • 1. FTIR spectroscopy reveals lipid droplets in drug resistant laryngeal carcinoma cells through detection of increased ester vibrational bands intensity.
    Rak S; De Zan T; Stefulj J; Kosović M; Gamulin O; Osmak M
    Analyst; 2014 Jul; 139(13):3407-15. PubMed ID: 24834449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin resistant human laryngeal carcinoma cells are cross resistant to curcumin due to reduced curcumin accumulation.
    Rak S; Cimbora-Zovko T; Gajski G; Dubravčić K; Domijan AM; Delaš I; Garaj-Vrhovac V; Batinić D; Sorić J; Osmak M
    Toxicol In Vitro; 2013 Mar; 27(2):523-32. PubMed ID: 23147641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [FTIR spectroscopic explorations of freshly resected laryngeal carcinoma tissues].
    Wu ZH; Cui CX; Liu TY; Jiang JH; Zhou XH; Pan QH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):901-4. PubMed ID: 19173989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance.
    Cimbora-Zovko T; Ambriović-Ristov A; Loncarek J; Osmak M
    Eur J Pharmacol; 2007 Mar; 558(1-3):27-36. PubMed ID: 17234182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of RhoB GTPase confers resistance to cisplatin in human laryngeal carcinoma cells.
    Cimbora-Zovko T; Fritz G; Mikac N; Osmak M
    Cancer Lett; 2010 Sep; 295(2):182-90. PubMed ID: 20303648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells.
    Brozovic A; Vuković L; Polančac DS; Arany I; Köberle B; Fritz G; Fiket Z; Majhen D; Ambriović-Ristov A; Osmak M
    PLoS One; 2013; 8(9):e76397. PubMed ID: 24086737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells.
    Toyozumi Y; Arima N; Izumaru S; Kato S; Morimatsu M; Nakashima T
    Int J Oncol; 2004 Sep; 25(3):721-8. PubMed ID: 15289875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTIR microspectroscopy defines early drug resistant human hepatocellular carcinoma (HepG2) cells.
    Junhom C; Weerapreeyakul N; Tanthanuch W; Thumanu K
    Exp Cell Res; 2016 Jan; 340(1):71-80. PubMed ID: 26708618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma.
    Zhang I; Cui Y; Amiri A; Ding Y; Campbell RE; Maysinger D
    Eur J Pharm Biopharm; 2016 Mar; 100():66-76. PubMed ID: 26763536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR.
    Tang XQ; Bi H; Feng JQ; Cao JG
    Acta Pharmacol Sin; 2005 Aug; 26(8):1009-16. PubMed ID: 16038636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocapsulated curcumin: oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat.
    Ghosh D; Choudhury ST; Ghosh S; Mandal AK; Sarkar S; Ghosh A; Saha KD; Das N
    Chem Biol Interact; 2012 Feb; 195(3):206-14. PubMed ID: 22197969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells.
    Li Y; Revalde JL; Reid G; Paxton JW
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):603-10. PubMed ID: 21116627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy.
    Baran Y; Ceylan C; Camgoz A
    Biomed Pharmacother; 2013 Apr; 67(3):221-7. PubMed ID: 23433849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Establishment of a human laryngeal carcinoma Hep-2/5-Fu cell line and the screening of differentially expressed genes].
    Chen J; Wang J
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Dec; 26(24):1130-3. PubMed ID: 23477120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of carboplatin resistance in human laryngeal carcinoma cells.
    Vuković L; Osmak M
    Neoplasma; 1999; 46(6):335-41. PubMed ID: 10732861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrimination between drug-resistant and non-resistant human melanoma cell lines by FTIR spectroscopy.
    Zwielly A; Gopas J; Brkic G; Mordechai S
    Analyst; 2009 Feb; 134(2):294-300. PubMed ID: 19173052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on best dose of X-ray for Hep-2 cells by using FTIR, UV-vis absorption spectroscopy and flow cytometry.
    Liu R; Tang W; Kang Y; Si M
    Spectrochim Acta A Mol Biomol Spectrosc; 2009 Aug; 73(4):601-7. PubMed ID: 19380250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of autophagy-potentiated chemosensitivity to cisplatin in laryngeal cancer Hep-2 cells.
    Kang R; Wang ZH; Wang BQ; Zhang CM; Gao W; Feng Y; Bai T; Zhang HL; Huang-Pu H; Wen SX
    Am J Otolaryngol; 2012; 33(6):678-84. PubMed ID: 22771248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): cross-resistance patterns.
    Beketić-Oresković L; Osmak M
    Neoplasma; 1994; 41(3):171-6. PubMed ID: 7935986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Empirical study of reverse effect on mediated multidrug resistance of U-2OS/ADM cells with curcumin in vitro].
    Xiao Y; Wang W
    Wei Sheng Yan Jiu; 2011 Jan; 40(1):103-6. PubMed ID: 21434326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.